Yuji Tanaka, Tsukuru Amano, Akiko Nakamura, Fumi Yoshino, Akie Takebayashi, Akimasa Takahashi, Hiroyuki Yamanaka, Ayako Inatomi, Tetsuro Hanada, Yutaka Yoneoka, Shunichiro Tsuji, Takashi Murakami
STUDY QUESTION: To what extent and via what mechanism does the concomitant administration of rapamycin (a follicle activation pathway inhibitor and antitumour agent) and cyclophosphamide (a highly toxic ovarian anticancer agent) prevent cyclophosphamide-induced ovarian reserve loss and inhibit tumour proliferation in a breast cancer xenograft mouse model? SUMMARY ANSWER: Daily concomitant administration of rapamycin and a cyclic regimen of cyclophosphamide, which has sufficient antitumour effects as a single agent, suppressed cyclophosphamide-induced primordial follicle loss by inhibiting primordial follicle activation in a breast cancer xenograft mouse model, suggesting the potential of an additive inhibitory effect against tumour proliferation...
May 11, 2024: Human Reproduction